Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Buoyed by strong performance of its key brands Januvia (sitagliptin) and Gardasil launched last year in India, U.S. drug giant Merck is going full throttle in its ambition to figure in the top five companies in India by 2015

You may also be interested in...



A Closer Look At Merck's Commercial Restructuring: What Happened To India?

In the latest overhaul of its commercial operations, Merck shared enthusiasm about prospects in emerging markets. But it did not include India, Turkey and Poland in its list of top 10 priority markets, a change from its vision shared just four years ago

As Tough Market And Policy Challenges Loom, J&J Names New India Leadership For Pharma Business

With former MSD hand Sanjiv Navangul as its new India CEO, experts believe J&J will make deeper inroads in the country. The new leader will be expected to make his way through regulatory bottlenecks at home while convincing global leadership to launch new drugs quickly for the Indian market.

Emerging Markets Earnings Roundup: Bayer And Merck (Part 3)

Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.

Related Content

Latest News
UsernamePublicRestriction

Register

SC070885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel